239 related articles for article (PubMed ID: 5081590)
1. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
Schmid FA; Hutchison DJ
Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
[No Abstract] [Full Text] [Related]
2. Sequential chemotherapy with cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in mice with advanced leukemia L1210.
Hoffman GS; Kline I; Gang M; Tyrer DD; Goldin A; Mantel N; Venditti JM
Cancer Chemother Rep; 1969 Oct; 53(5):265-71. PubMed ID: 5377613
[No Abstract] [Full Text] [Related]
3. Value of cytosine arabinoside (NSC-63878) plus 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) therapy in advanced murine L1210 leukemia and enhancement of the combination with sequential doses of methotrexate (NSC-740) or 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Kline I; Woodman RJ; Gang M; Cysyk RL; Venditti JM
Cancer Chemother Rep; 1973; 57(3):291-8. PubMed ID: 4751255
[No Abstract] [Full Text] [Related]
4. Chronochemotherapy of L1210 leukemic mice with cytosine arabinoside or cyclophosphamide.
Rose WC; Trader MW; Laster WR; Schabel FM
Cancer Treat Rep; 1978 Sep; 62(9):1337-49. PubMed ID: 688277
[No Abstract] [Full Text] [Related]
5. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
Shackney SE
Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
[No Abstract] [Full Text] [Related]
6. Influence of the stage of advancement of leukemia L1210 in mice on the optimal schedule of treatment of cytosine arabinoside (NSC-63878).
Kline I; Woodman RJ; Gang M; Sirica A; Venditti JM; Goldin A
Cancer Chemother Rep; 1972 Jun; 56(3):327-34. PubMed ID: 19051491
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy in sequence for the treatment of L1210 leukemia.
Roberts D; Hilliard SL
Cancer Res; 1978 Aug; 38(8):2317-20. PubMed ID: 667827
[No Abstract] [Full Text] [Related]
8. Dose-related synergism of cytosine arabinoside and methotrexate against murine leukemia L1210.
Avery TL; Roberts D
Eur J Cancer (1965); 1974 Jul; 10(7):425-9. PubMed ID: 4457345
[No Abstract] [Full Text] [Related]
9. Combination chemotherapy with cytosine arabinoside, L-asparaginase, and 6-azauridine for transplantable murine leukemias.
Avery TL; Roberts D
Cancer Res; 1973 Apr; 33(4):791-9. PubMed ID: 4696479
[No Abstract] [Full Text] [Related]
10. Studies of the L1210 antileukemic activity of O-2,2'-cyclocytidine, monoacetate (anhydro-ara-C; NSC-129220)--comparison with cytosine arabinoside (NSC-63878) with respect to treatment schedule dependency.
Venditti JM; Baratta MC; Greenberg NH; Abbott BJ; Kline I
Cancer Chemother Rep; 1972 Aug; 56(4):483-92. PubMed ID: 5081591
[No Abstract] [Full Text] [Related]
11. Influence of mitotic cycle inhibitors on the antileukemic activity of cytosine arabinoside (NSC-63878) in mice bearing leukemia L1210.
Vadlamudi S; Goldin A
Cancer Chemother Rep; 1971 Dec; 55(5):547-55. PubMed ID: 5159846
[No Abstract] [Full Text] [Related]
12. Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
Dombernowsky P; Nissen NI
Eur J Cancer (1965); 1976 Mar; 12(3):181-8. PubMed ID: 939236
[No Abstract] [Full Text] [Related]
13. Combined interferon--antimetabolite therapy of murine L1210 leukemia.
Slater LM; Wetzel MW; Cesario T
Cancer; 1981 Jul; 48(1):5-9. PubMed ID: 6165457
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
Glae GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
J Natl Cancer Inst; 1976 Dec; 57(6):1363-6. PubMed ID: 187805
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of antileukemic agents in advanced leukemia L1210 in mice. X.
Kline I; Gang M; Tyrer DD; Venditti JM; Artis EW; Goldin A
Cancer Chemother Rep 2; 1972 Nov; 3(1):1-69. PubMed ID: 4660732
[No Abstract] [Full Text] [Related]
16. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
[No Abstract] [Full Text] [Related]
17. Influence of 2-chloro-2'-deoxyadenosine alone and in combination with cyclophosphamide or methotrexate on murine leukemia L1210.
Góra-Tybor J; Robak T; Warzocha K; Grieb P
Arch Immunol Ther Exp (Warsz); 1994; 42(1):39-42. PubMed ID: 7503633
[TBL] [Abstract][Full Text] [Related]
18. Influence of route of administration on antileukemic activity of cytosine arabinoside (NSC-63878) in advanced leukemia L1210 in mice.
Kline I; Tyrer DD; Gang M; Venditti JM; Goldin A
Cancer Chemother Rep; 1968 Apr; 52(3):399-404. PubMed ID: 5670722
[No Abstract] [Full Text] [Related]
19. Criteria associated with destruction of leukemia and solid tumor cells in animals.
Skipper HE
Cancer Res; 1967 Dec; 27(12):2636-45. PubMed ID: 6082300
[No Abstract] [Full Text] [Related]
20. Cyclophosphamide (NSC-26271), vincristine (NSC-67574), cytosine arabinoside (NSC-63878), and prednisone (NSC-10023) (COAP) combination chemotherapy for acute leukemia in adults.
Whitecar JP; Bodey GP; Freireich EJ; McCredie KB; Hart JS
Cancer Chemother Rep; 1972 Aug; 56(4):543-50. PubMed ID: 5081596
[No Abstract] [Full Text] [Related]
[Next] [New Search]